Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer

Background In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity. Patients and methods We retrospectively reviewed the records of 30 patients with LMBC treated with intra-hepati...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2008-07, Vol.110 (1), p.135-142
Main Authors: Maes, Toon, Wildiers, Hans, Heye, Sam, Demey, Wim, Maleux, Geert, Neven, Patrick, Van Oosterom, Allan T., Paridaens, Robert
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating - administration & dosage
Biological and medical sciences
Breast cancer
Breast Neoplasms - pathology
Cancer research
Cancer therapies
Cell growth
Chemotherapy
Clinical outcomes
Clinical Trial
Clinical trials
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gynecology. Andrology. Obstetrics
Humans
Liver
Liver Neoplasms - drug therapy
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Mammary gland diseases
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Mitomycin - administration & dosage
Mitomycin - adverse effects
Oncology
Retrospective Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity. Patients and methods We retrospectively reviewed the records of 30 patients with LMBC treated with intra-hepatic MMC at our institution. MMC (12 mg) was administered by transcatheter bolus infusion into the hepatic arteries every 4 weeks. Tumour response according to RECIST criteria, progression free survival (PFS), overall survival (OS) and duration of response (DR) were used to evaluate efficacy. Results There was a local response in the liver and a global response in respectively 33 and 26%. The median PFS, DR and OS were 3, 4 and 7 months, respectively. There was more benefit in patients without documented metastases outside the liver and without severe liver dysfunction. Thrombocytopenia, leucocytopenia and an allergic reaction were observed after MMC administration in 20 (67%), 12 (40%) and 4 patients (13%), respectively. Conclusion Intra-hepatic MMC bolus infusion as treatment of extensive LMBC is associated with limited toxicity and has a significant response rate in the liver. Prospective investigations are required to define the place of this modality for treating patients with breast cancer liver metastases.
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-007-9707-4